Posted by Michael Wonder on 18 Nov 2024
Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR mutated lung cancer
18 November 2024 - Recommendation based on LAURA Phase 3 trial results which showed Tagrisso extended median progression-free survival to more than three years.
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.
